GlassScriptPhysician profile
Edward J Peters
NPI 1255342184
$3,646.51
in general payments reported to CMS, 2019-2025
28 companies · $1,300 in 2025
The $1,300 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $347 · 2021: $113 · 2022: $225 · 2023: $391 · 2024: $611 · 2025: $1,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,282 · Consulting Fee: $19.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,281.71 |
| Consulting Fee | $19.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,269.70 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $561.74 | 2019-2025 | |
| Genzyme Corporation | $140.90 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.49 | 2019-2022 | |
| Genentech USA, INC. | $128.48 | 2020-2025 | Xolair |
| Grifols USA, LLC | $126.75 | 2019-2025 | Xembify, Gamunex-C, Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $120.44 | 2025 | Dupixent |
| Pfizer INC. | $115.31 | 2019-2024 | |
| Csl Behring | $113.51 | 2022-2025 | Haegarda, Andembry, Hizentra |
| Alk-Abello, INC | $98.07 | 2019-2025 | Ragwitek, Odactra, Grastek |
| Blueprint Medicines Corporation | $94.81 | 2023-2025 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $94.13 | 2019-2025 | Fasenra |
| Verona Pharma, INC. | $79.93 | 2025 | Ohtuvayre |
| Insmed, INC. | $74.96 | 2025 | Arikayce, Brinsupri |
| Amgen INC. | $69.96 | 2025 | Tezspire |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $67.59 | 2024 | Adbry |
| Takeda Pharmaceuticals U.S.A., INC. | $51.90 | 2024-2025 | Takhzyro, Hyqvia, Glassia |
| Mylan Specialty L.P. | $46.49 | 2019 | |
| Covis Pharma Gmbh | $45.26 | 2022 | |
| Octapharma USA, INC. | $39.70 | 2025 | Panzyga, Octagam Immune Globulin (Human) |
| Organon LLC | $28.55 | 2025 | |
| Kaleo, INC. | $26.39 | 2023 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $22.87 | 2019 | |
| Incyte Corporation | $20.72 | 2021 | |
| Adma Biomanufacturing LLC | $19.72 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $19.40 | 2025 | Neffy |
| Hospira, INC. | $15.70 | 2024 | |
| Philips North America LLC | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.